Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00103337 · ClinicalTrials.gov registry record · Phase 2
Cilengitide in Treating Patients With Metastatic Prostate Cancer
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 106
- Enrollment target
NCT00103337: Completed Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT00103337 is a Phase 2 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 106 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00103337, a Phase 2 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 106 participants
- Enrollment target
Study Summary
This randomized phase II trial is studying how well cilengitide works in treating patients with metastatic prostate cancer. Cilengitide may stop the growth of prostate cancer by blocking blood flow to the tumor
Interventions
- OTHER laboratory biomarker analysis
- DRUG cilengitide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 106 participants |
| Start Date | 2005-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00103337
The ClinicalTrials.gov registry entry for NCT00103337 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 106 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which laboratory biomarker analysis is the first listed.
NCT00103337 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00103337 about?
NCT00103337 is a clinical study titled "Cilengitide in Treating Patients With Metastatic Prostate Cancer". This randomized phase II trial is studying how well cilengitide works in treating patients with metastatic prostate cancer. Cilengitide may stop the growth of prostate cancer by blocking blood flow to the tumor
What is the current status of trial NCT00103337?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 106 participants. The study started on 2005-01.
What interventions are being tested in trial NCT00103337?
The interventions under investigation include: laboratory biomarker analysis (OTHER), cilengitide (DRUG).
Who is sponsoring clinical trial NCT00103337?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.